Credit: Canva
We’ve all heard the joke at some point — women take longer in the bathroom because they “pee more.” But is there any truth behind this bathroom stereotype? As it turns out, science is more complex than that, and the answer lies deep within the structure of our kidneys.
Biologically speaking, men generally have larger kidneys than women. But does that mean they produce more urine? Not necessarily.
A recent review of autopsy data has revealed some interesting findings. While men do tend to have physically larger kidneys, researchers aren’t entirely sure if this difference holds up once body size — such as height, weight, or body surface area (BSA) — is taken into account. In other words, just because a man has a bigger kidney doesn’t automatically mean it's more efficient or produces more urine.
However, here's where it gets interesting: When kidney size is adjusted relative to body size, men may not actually have significantly larger kidneys than women. And in clinical settings, women often show better kidney health outcomes over time. Studies suggest that women are less likely to develop or progress to chronic kidney disease (CKD), even though they may report more frequent urination.
Hormonal fluctuations during menstruation, pregnancy, or menopause also play a significant role in urinary patterns. Estrogen, for instance, affects the urinary tract and can make women more sensitive to the urge to go.
Ultimately, urination is a deeply personal — and variable — experience. If you find yourself making more frequent bathroom visits than usual, regardless of gender, it might be worth discussing with a healthcare provider.
Because when it comes to your health, every drop matters.

Credit: iStock
Credit: iStock
A recent study has found proof that an autoimmune reaction is triggering certain neurological symptoms seen in some long COVID patients. The study, conducted in healthy mice, found that the mice exhibited symptoms mirroring those of affected patients to some extent.
While it has been a long time since the end of the COVID pandemic, its effects continue to linger even today. Several patients who contracted COVID continue to suffer.
A US NIH-funded research group, directed by Drs. Akiko Iwasaki and Tamas L. Horvath of the Yale University School of Medicine and Dr. David Putrino of the Icahn School of Medicine at Mount Sinai recently found that autoantibodies could be triggering these neurological symptoms in some long COVID patients.
Antibodies, in a healthy person, help fight infections. In patients with autoimmune diseases, these antibodies target the body’s own tissues. They are called autoantibodies.
The study also discovered that patients who had these autoantibodies are more likely to experience similar symptoms. For example, people with autoantibodies are more likely to face symptoms like loss of taste and smell. They are also more likely to experience nausea and joint pain.
The researchers conducted the study by transferring purified antibodies from long COVID patients into healthy mice. It was discovered that the mice developed the following changes that resembled the donors' symptoms:
The recent breakthrough in long COVID research has brought the healthcare industry one step closer to personalizing care for those affected.
Dr. Putrino says, “Our study now shows that if you are in a subgroup of Long COVID patients who have autoantibodies circulating in your body, this is a quantifiable sign that you may be a good candidate for these drugs.”
The study finds that cardiovascular diseases were more common among long COVID patients. It concluded that 11.9% of those with long COVID have CVD compared to 6.8% without this condition.
Specifically, it further revealed that long COVID was associated with a higher risk of chest pain and heart attack, but not coronary heart disease and stroke.
Credit: iStock
A recent study has found proof that an autoimmune reaction is triggering certain neurological symptoms seen in some long COVID patients. The study, conducted in healthy mice, found that the mice exhibited symptoms mirroring those of affected patients to some extent.
While it has been a long time since the end of the COVID pandemic, its effects continue to linger even today. Several patients who contracted COVID continue to suffer.
A US NIH-funded research group, directed by Drs. Akiko Iwasaki and Tamas L. Horvath of the Yale University School of Medicine and Dr. David Putrino of the Icahn School of Medicine at Mount Sinai recently found that autoantibodies could be triggering these neurological symptoms in some long COVID patients.
Antibodies, in a healthy person, help fight infections. In patients with autoimmune diseases, these antibodies target the body’s own tissues. They are called autoantibodies.
The study also discovered that patients who had these autoantibodies are more likely to experience similar symptoms. For example, people with autoantibodies are more likely to face symptoms like loss of taste and smell. They are also more likely to experience nausea and joint pain.
The researchers conducted the study by transferring purified antibodies from long COVID patients into healthy mice. It was discovered that the mice developed the following changes that resembled the donors' symptoms:
The recent breakthrough in long COVID research has brought the healthcare industry one step closer to personalizing care for those affected.
Dr. Putrino says, “Our study now shows that if you are in a subgroup of Long COVID patients who have autoantibodies circulating in your body, this is a quantifiable sign that you may be a good candidate for these drugs.”
The study finds that cardiovascular diseases were more common among long COVID patients. It concluded that 11.9% of those with long COVID have CVD compared to 6.8% without this condition.
Specifically, it further revealed that long COVID was associated with a higher risk of chest pain and heart attack, but not coronary heart disease and stroke.
© 2024 Bennett, Coleman & Company Limited